Cat4CanCenter
Financiado
Catalysis for Cancer Treatment.
The increased incidence and mortality of tumors that do not respond to standard of care or other targeted therapies is a major challenge in clinical management of these cancer patients. In order to provide innovative therapeutic a...
The increased incidence and mortality of tumors that do not respond to standard of care or other targeted therapies is a major challenge in clinical management of these cancer patients. In order to provide innovative therapeutic avenues for treatment refractory patients, it is urgent to develop novel mechanisms of anticancer drugs mode of action that will overcome the drawbacks of current therapies. In Cat4CanCenter, we will merge the research fields of metal-based catalysis for drug development and innovative delivery routes with cancer biology and immunology, applied to one of the deadliest cancers, glioblastoma (GBM), a fatal primary brain tumor for which no curing therapy exists, due to its location within the brain parenchyma and complex tumor microenvironment. Many potential drugs failed in the clinic due to their inherent toxicity and off-target side-effects, which add up to the challenges in reaching the protected brain site. Recently, innovative catalyst design enabled synthetic transformations in the presence of biological molecules. In Cat4CanCenter we will develop four innovative approaches to treat GBM. This new methodology requires the design of cage protected catalysts that will be delivered to targeted cell types using advanced lipid nanoparticle technology. Next, the catalysts will convert nontoxic prodrugs into active drugs within the GBM bulk. Our groundbreaking strategy aims for successful therapies to treat glioblastoma, by developing complementary approaches to therapeutically tackle the complexity of this disease. The new strategies, catalysts and prodrIn this project we explore a new avenue to treat glioblastoma, which is the most difficult cancer to target. In a collaborative program we develop biomimetic transition metal catalysts (key expertise 1) that will be delivered using smart strategies such as lipid nanoparticles (key expertise 2) to generate cancer drug in vivo. The glioblastoma biology will be studies in detail (key expertise 3).
ver más
Duración del proyecto: 71 meses
Fecha Inicio: 2024-01-01
Fecha Fin: 2029-12-31
Fecha Fin: 2029-12-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-01-01
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2023-SyG:
ERC Synergy Grants
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
11M€
Líder del proyecto
UNIVERSITEIT VAN AMSTERDAM
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5